Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clonal evolution of mycosis fungoides into peripheral T-cell lymphoma: evidence from next-generation sequencing in two cases.

Annals of hematology·2026
Same author

A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial.

Cancers·2026
Same author

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Blood·2026
Same author

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England)·2026
Same author

A convolutional neural network for fully automated total metabolic tumor volume delineation in patients with aggressive Non-Hodgkin lymphoma.

European journal of nuclear medicine and molecular imaging·2026
Same author

Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Related Experiment Video

Updated: May 16, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K

Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET

Jakoba J Eertink1, Martijn W Heymans2, Sanne E Wiegers1

  • 1Amsterdam UMC location Vrije Universiteit Amsterdam, Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam.

Haematologica
|May 15, 2025
PubMed
Summary
This summary is machine-generated.

Identifying diffuse large B-cell lymphoma (DLBCL) patients at high risk of treatment failure is crucial. New models incorporating radiomic features and interim PET scans improve early risk prediction for better treatment decisions.

More Related Videos

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.7K

Related Experiment Videos

Last Updated: May 16, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.7K

Area of Science:

  • Oncology
  • Radiology
  • Medical Imaging

Background:

  • Accurate risk stratification in diffuse large B-cell lymphoma (DLBCL) is vital for timely treatment escalation.
  • The International Metabolic Prognostic Index (IMPI) shows promise but may be enhanced by additional predictive factors.
  • Radiomic features and early treatment response could refine prognostic models.

Purpose of the Study:

  • To develop and evaluate dynamic risk prediction models for DLBCL treatment failure.
  • To assess the added value of radiomic features and interim PET (iPET) response beyond existing prognostic indices.
  • To compare novel models against the IMPI and ClinicalPET models.

Main Methods:

  • Utilized data from the PETRA database of newly diagnosed DLBCL patients treated with R-CHOP.
  • Developed Cox regression models to identify optimal transformations of Dmaxbulk, SUVpeak, and ΔSUVmax.
  • Validated models using cross-validated c-index for discrimination and Akaike Information Criterion (AIC) for model fit.
  • Compared baseline and interim PET-based risk models.

Main Results:

  • The best baseline model included age, metabolic tumor volume (MTV), and Dmaxbulk (c-index 0.70).
  • Incorporating iPET response (ΔSUVmax) significantly improved outcome prediction (c-index 0.74).
  • The dynamic model demonstrated wider segregation of Kaplan-Meier curves and better risk classification accuracy.

Conclusions:

  • A dynamic risk assessment incorporating baseline and interim PET features offers superior outcome prediction in DLBCL.
  • Radiomic features and early treatment response provide valuable prognostic information.
  • These findings support the development of more personalized treatment strategies for DLBCL.